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DNA.[1] These GE tools include ZFNs (zinc 
finger nucleases), TALENs  (transcription 
activator-like effector nucleases), CRISPR 
(clustered regulatory interspaced short 
palindromic repeats)/Cas9 (CRISPR-asso-
ciated proteins), and related CRISPR/Cas 
systems. Among these GE tools, CRISPR/
Cas systems are extensively used in com-
parison with other methods because they 
are cost-effective, easy to use, and do not 
require specialist skills.[2] The CRISPR/
Cas9 system requires an RNA designing 
with a short guide sequence (sgRNA) that 
directs a Cas9 nuclease for cleaving any 
target sequence.[3] Cas9 is a CRISPR RNA-
guided endonuclease that cuts dsDNA 
targets complementary to the sgRNAs[4] 
and is being exploited for GE in bacteria[5] 
and in eukaryotic cells,[6] including animal 
cells,[7] mammalian systems,[8,9] and 
plants.[10,11]
Base editing is a quite different and 
the most recent GE system, which has 
been widely used for introducing highly predictable and pre-
cise single nucleotide substitutions at genomic targets without 
requiring donor DNA templates, double-strand breaks (DSBs) 
or dependence on homology-directed repair (HDR) and non-
homologous end joining (NHEJ).[12] Base editing technology is 
being used in various organisms and cell lines.[12,13] It has been 
considered more effective than HDR-mediated base-pair sub-
stitution.[13] To date, several base editing systems, for instance 
BE3,[14] BE4,[15] Targeted-AID,[16] and dCpf1-BE[17] have been 
used in various organisms including major crops. These sys-
tems utilize Cas9 or Cpf1 systems for recruiting cytidine deam-
inases, which generate specific C–T alterations by using DNA 
mismatch repair pathways.[14–17]
2. The Fidelity of CRISPR/Cas Systems
CRISPR/Cas9 nucleases have been used for GE in a wide diver-
sity of living organisms, including major crops. Nevertheless, 
these GE systems can introduce unexpected off-target muta-
tions. Several reports revealed CRISPR/Cas9 system is more 
prone to off-target effects than TALENs and ZFNs because it 
is a monomer, whereas the ZFN and TALEN assemblies are 
dimeric, facilitating identification of shorter target sequences. 
Life sciences have been revolutionized by genome editing (GE) tools, including 
zinc finger nucleases, transcription activator-Like effector nucleases, and 
CRISPR (clustered regulatory interspaced short palindromic repeats)/Cas 
(CRISPR-associated) systems, which make the targeted modification of 
genomic DNA of all organisms possible. CRISPR/Cas systems are being widely 
used because of their accuracy, efficiency, and cost-effectiveness. Various 
classes of CRISPR/Cas systems have been developed, but their extensive use 
may be hindered by off-target effects. Efforts are being made to reduce the  
off-target effects of CRISPR/Cas9 by generating various CRISPR/Cas systems 
with high fidelity and accuracy. Several approaches have been applied to detect 
and evaluate the off-target effects. Here, the current GE tools, the off-target 
effects generated by GE technology, types of off-target effects, mechanisms of 
off-target effects, major concerns, and outcomes of off-target effects in plants 
and animals are summarized. The methods to detect off-target effects, tools 
for single-guide RNA (sgRNA) design, evaluation and prediction of off-target 
effects, and strategies to increase the on-target efficiency and mitigate the  
off-target impact on intended genome-editing outcomes are summarized.
© 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. This is an open access article under the terms of the  Creative 
Commons Attribution License, which permits use, distribution and 
 reproduction in any medium, provided the original work is properly cited.
1. E-CRISP/Cas Systems
Genome editing (GE) tools have modernized the genetics 
by their potential use in the precise modification of genomic 
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The Cas9 complex has been reported to bind to unintended 
regions and initiate cleavage, known as off-target effects.[3] 
Off-targets are regions of gRNA that are highly homologous 
to the proposed on-target regions. Normally off-target regions 
have up to six mismatches compared with on-target sites.[18] 
Off-targets with fewer mismatches have a tendency for more 
prominent binding and cleavage. However, a variety of tools 
are being developed for finding potential off-target regions for 
given gRNA sequences, and so allow fewer mismatches.[18] The 
off-target effects of Cas9 were first studied in human cancer 
cell lines,[19–21] where the frequency of those off-target effects 
was remarkably high, because of incorrectly functioning DNA 
repair pathways in tumor cells.[22]
In base editing system, off-target can result from gRNA 
dependent or gRNA independent editing events.[23–25] A variety of 
strategies have been widely used for decreasing gRNA-dependent 
off-target base editing,[25,26] for instance the incorporation of 
mutations that enhance the specificity of DNA into the Cas9 
component of base editors (BEs),[25,27,28] adding 5′-guanosine 
nucleotides to the sgRNA,[25] or delivering the BEs as a ribo-
nucleoprotein (RNP) complex.[25,27,28] Off-target editing based 
on gRNA-independent arises by Cas9-independent mannered 
binding to the deaminase domain of a BE to C or A bases.[23,24,26]
3. Types of Off-Target Effects
Off-target regions have previously been classified into three 
major types. The first includes regions at other PAMs (5′-NGG-3′) 
which have substitutions or mismatches.[20,29] The second type 
includes the regions at other PAMs (5′-NGG-3′) which contain 
insertions and/or deletions (indels) as comparison with target 
DNA or gRNA spacer.[30] The DNA or RNA forms a small bulge 
with the residual nucleotides, and they correctly anneal, facili-
tating Cas9 activity. However, the off-target activities detected 
at these sites are sometimes higher than on-target activi-
ties.[30] The third type regards the cutting of sequences with 
the different PAM sites (5′-NAG-3′).[20,29] However, it has also 
been proposed that there are two types of off-target effects by 
CRISPR. The first type is the expected off-targets in genomic 
regions which have high sequence similarity with the target. 
The second type includes the unexpected off-targets in genomic 
regions which are not related to the target.[31]
4. Mechanism of Off-Target Effects  
by CRISPR/Cas System
Accurate genome sequence information is essential for predic-
tion of off-target effects. Generally, the CRISPR/Cas system 
accepts no less than 3 mismatches in a 20-base pair (bp) 
target DNA sequence. However, Cas9 may induce undesir-
able off-target mutations because the sgRNAs recognize DNA 
sequences based on one to some nt mismatches, albeit with 
decreased binding and cleavage activity of the nuclease.[6,29,32] 
The initial interaction between Cas9 and DNA is mediated by 
recognition and the binding at PAM site, which sequentially 
enables the melting of PAM-proximal DNA and allows the 
directed probing of combining between the crRNA and the 
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potential target editing sequences, forming a stable R-loop.[33–35] 
The binding and cleavage show different complementarity 
requirements within the 20 bp target. High stable binding 
needs however seven to nine matched bases in PAM-proximal 
regions. It has been shown that as few as four mismatches 
in the PAM-distal end hinder cleavage but not binding.[36,37] 
CRISPR/Cas9 specificity mainly relies on the sgRNA seed 
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sequence within 10–12 bp directly 5′ of the NGG PAM-prox-
imal region.[38] When the sgRNA sequence recognizes partial 
mismatches outside the seed sequence instead of on-target 
sites, then off-target edits will be produced.[39] DNA bubbles 
are involved in inducing binding and cleavage of off-target 
sequence at these sites. The partly unwound or melted DNA 
helps in recruiting Cas9 for binding and cleaving formerly 
hidden cryptic off-target sites.[40] The mechanism of off-target 
editing by the CRISPR/Cas system is illustrated in Figure 1.
4.1. Reasons for Off-Target Effects
The targeting fidelity of Cas9 is considered to be highly deter-
mined by the 20 nt sgRNA and the PAM sites adjacent to the 
target sequence of the genome. However, the off-target DNA 
cleavage will still happen on DNA sequences with up to 3–5 bp 
mismatches in the PAM-distal region of the sgRNA targeting 
sequence.[8,20] Moreover, the cleavage of off- and on-target 
sites can be affected by different guide RNA (gRNA) struc-
tures.[38] Furthermore, it has been suggested by the studies of 
crystal structure and experiments of single-molecule DNA cur-
tain that the PAM sites are crucial for the binding activity of 
Cas9; and the seed sequence directly adjacent to PAM which 
 corresponds to crRNA complementary recognition sequence 
(at 3′ end), is also essential for subsequent binding of Cas9, 
 formation of R-loop and the nuclease activities in Cas9.[41–43]
Additionally, many reports on off-targets report that the type 
of mismatch type and its distance from the PAM sequence have 
significant importance. This information enables the devel-
opment of a variety of off-target scoring methods, aiding the 
 selection of gRNAs with off-target predictions.[18,44] The generation 
of DSBs in off-target locations can be occurred due to the binding 
of Cas9 protein to PAM-like sequences and/or the binding of 
gRNA to sequences which are identical to the target site.
4.2. Major Concerns/Outcomes of Off-Target Effects
CRISPR/Cas systems show great potential in GE, but their 
off-targeting may cause severe problems for the host organ-
isms. Off-targeting can lead to chromosomal rearrangements, 
causing damage at imperfectly matched genomic loci and 
limiting GE application for therapeutic purposes.[45,46] As well 
as interfering with chromosome stability, off-target effects may 
cause loss of functional-gene activity that causes diverse physi-
ological or signaling abnormalities[29,47] (Figure 2). It is there-
fore vital to design an optimum sgRNA for achieving high 
on- targeting with no or little possibility for off-target effects.[48]
4.2.1. In Plants
CRISPR/Cas9 has been used for successful editing of more 
than 25 plant species and 100 genes to create variety of desir-
able traits in major crops.[49,50] However, the potential off-target 
effects are the recent concern for the applications of CRISPR/
Cas9 in plant,[51] and this problem must be addressed if the 
techno logy is to be adopted for extensive use in gene therapy and 
crop breeding.[52–54] Unlike gene therapy and clinical research in 
humans, research in plants is free from the same ethic issues, 
and there may be a higher tolerance for off-target GE effects. 
It is critical to validate the phenotypic variations of interest for 
basic plant research. However, crop molecular breeding enables 
Adv. Sci. 2020, 7, 1902312
Figure 1. Mechanism of off-target editing. CRISPR/Cas9 systems accept at least three mismatches in a 20 bp DNA target sequence. Cas9 may intro-
duce unexpected off-target mutations because sgRNAs recognize DNA sequences with one to a few nucleotide mismatches. a,b) PAM binding and 
recognition mediates the initial Cas9–DNA interaction, which leads to PAM-proximal DNA melting. c) gRNA binding on target site initiates DNA 
unwinding. d) A stable R-loop was formed between the crRNA and potential target sites. e) The sgRNA sequence recognizes partial mismatches 
outside the seed sequence instead of on-target sites. f) Off-target editing is generated as a result of mismatch recognition by sgRNA. Created with 
BioRender.com.
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the elimination of off-target mutations or spontaneous muta-
tions causing inferior traits, via the selection of phenotypes 
during the breeding process. Therefore off-target effects do not 
pose a major problem for practical crop breeding.[55,56]
4.2.2. In Animals
Unforeseen off-target edits can be generated when the 
CRISPR/Cas systems do not cleave only the target region, and 
may cause potentially harmful effects, for example by activation 
of oncogenes.[57,58] As mentioned above, off-target mutations 
may cause genome instability and disrupt gene function.[43] 
The sgRNA-dependent and -independent events can affect 
the overall stability of genomes in edited cells. For instance, 
sgRNA-independent abnormalities, such as transduction of 
Cas9-sgRNA complexes, can be induced by different kinds of 
stresses  generated in different experimental conditions.[58] Off-
targeting is a primary concern when applying CRISPR/Cas sys-
tems to clinical and biomedical applications.
5. Methods/Techniques to Detect Off-Target 
Effects
A variety of in vitro bulk assays, single-molecule, computational, 
and crystallography approaches are being used to understand the 
mechanism of binding and cleaving of targets by the Cas9 com-
plex.[33–37,40,41,60] Different kinds of methods are used to detect 
and quantify off-target effects caused by CRISPR/Cas9 and other 
CRISPR/Cas systems, and are described below (Table 1).
5.1. Whole-Genome Sequencing (WGS)
WGS is an unbiased and direct method for assessing muta-
tions. However, it can detect only small percentages of 
 off-targets from bulk cells subjected to GE, and is impractical 
for distinguishing single nucleotide variants (SNVs) from those 
of sequencing errors and those that are naturally occurring. 
Therefore, it is important to seriously investigate the genetic 
background before assessment of off-targets.[59] WGS has 
Adv. Sci. 2020, 7, 1902312
Figure 2. Major concerns/outcomes of off-target effects. CRISPR/Cas systems usually offer great potential in genome editing, but off-target activity, 
causing unintended consequences, is limiting its applications for therapeutic and agricultural purposes. a) CRISPR/Cas9 with a specific sgRNA may 
sometimes bind and edit at a site other than its target sequence, known as off-target editing. This may result in unexpected serious consequences, 
such as the activation/inactivation of off-target genes which can result in lethal or undesired phenotypes, or the activation of oncogenes causing cancer 
in animals. b) CRISPR/Cas9 that accurately edits its target gene is termed on-target editing. CRISPR/Cas9 has been used in wide range of plants and 
animals due to its robust on-target editing efficiency. On-target editing leads to desired targeted phenotypes. Created with BioRender.com.
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been applied for detection of off-target mutations by Cas9 in a 
variety of plants, including Arabidopsis,[61] rice,[62] tomato[63] and 
cotton.[64] However, WGS has only the ability to detect higher 
frequency off-target sites with high reliability, and lacks the 
sensitivity required for the detection of off-target sites in bulk 
populations.[18,65] WGS has the potential for detecting all types of 
off-target base editing in cells or whole higher organisms when 
performed on genomic DNA from many independent cells.
5.2. Genome-Wide, Unbiased Identification of DSBs Enabled by 
Sequencing (GUIDE-seq)
GUIDE-seq detects DSBs caused by nuclease activity based 
on the integration of double-stranded oligodeoxynucleotides 
(dsODNs) into DSBs sites mediated by NHEJ , followed by the 
tagged DNA fragments amplification and sequencing.[22] Cel-
lular assays, such as GUIDE-Seq,[29] test nuclease cutting in 
a cellular context but rely on the integration of an exogenous 
DNA oligo that is inefficient in primary cells and not applicable 
in vivo. Furthermore, the cotransfection of additional exog-
enous DNA would not currently be used in human therapy for 
ethical reasons, and may affect overall editing outcomes.[66]
5.3. Digested Genome Sequencing (Digenome-seq)
Digenome-seq is an unbiased, robust, cost-effective, sensitive, 
and reproducible method to profile off-target effects genome-
wide of Cas9 and other programmable nucleases. Digenome-
seq is based on DNA cleavage rather than binding and this 
method is applied in the whole genomic context. Notably, 
Digenome-seq captures potential off-target sites with an RNA/
DNA bulge. The Digenome-seq is sensitive enough for detec-
tion of off-target level where the induced indels are of 0.1% or 
lower frequency, which is almost the limit of detection of high-
throughput sequencing strategy.[67]
5.4. Bless
BLESS is direct in situ Breaks Labeling, Enrichment on Strepta-
vidin, and next-generation Sequencing and has been used in 
mouse and human cells with different sequencing platforms 
and DSBs-inducing agents. BLESS has widely been used for 
detection of DSBs induced by Sce endonuclease, complex 
genome-wide DSB landscapes and telomere ends. The direct in 
situ labeling avoids the labeling of DSBs which are artificially 
formed during the extraction of genomic DNA; so minimizing 
the risk of false positives.[68]
5.5. SITE-Seq
SITE-Seq is a method based on biochemical strategy that iden-
tifies the tagged genomic DNA ends and selective enrichment 
by sequencing (SITE-Seq) for identification of cleavage sites of 
Cas9 in purified genomic DNA. In SITE-Seq, genomic DNA is 
digested with various sgRNP concentrations, from limitation 
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to saturation, and therefore permits the recovery of low- and 
high-cleavage-sensitivity off-target sites. SITE-Seq has been 
involved in producing highly enriched sequencing libraries for 
sgRNP cleavage fragments that enable specificity profiling with 
minimal read depth, which is crucial for the implementation of 
SITE-Seq as a high-throughput guide selection tool.[69]
5.6. CIRCLE-seq
CIRCLE-seq is a rapid, accessible, comprehensive, and highly 
sensitive in vitro detecting strategy to identify off-target muta-
tions of CRISPR/Cas9 in a genome-wide scale.[70] CIRCLE-seq 
makes use of next-generation sequencing technology, and has 
widely been used for the identification of off-target mutations 
involved with cell-type-specific SNPs, which demonstrates the 
importance and feasibility for the generation of personalized 
specificity profiles.[69] Moreover, CIRCLE-seq could be applied 
for the detection of off-target sites without presence of a ref-
erence genome or organisms lacking full genomic sequence 
availability.[70]
5.7. DISCOVER-Seq
DISCOVER-Seq is a powerful, sensitive assay for an unbiased 
identification of off-target sites in cellular models. For example, 
it has been used in vivo following adenoviral gene editing of 
mouse livers, paving the way for real-time discovery of off- 
targets during therapeutic gene editing. DISCOVER-Seq has 
been used with various types of Cas nucleases. DISCOVER-Seq 
reliably detects off-target editing from a variety of gRNAs, mul-
tiple Cas nucleases, in human and mouse cells[71] and so poten-
tially other species with large genomes.
5.8. GOTI
GOTI is an approach that evaluates the off-target effects which 
are induced by CBE3, ABE 7.10, and CRISPR/Cas9.[23,72] GOTI 
has been used for the detection of off-target mutations of 
mouse embryos at early stage by using either BEs or CRISPR/
Cas9. Moreover, GOTI can evaluate off-targets in the cell pop-
ulation derived from a single gene-edited blastomere. GOTI 
could be useful for examining the off-target effects of various 
gene-editing tools without the interference of SNPs present in 
different individuals.[24]
5.9. EndoV-seq (Endonuclease V Sequencing)
EndoV-seq is a method widely used for the investigation of 
genome-wide specificity of ABE, where Endonuclease V (EndoV) 
digests in vitro deaminated genomic DNA before being sub-
jected to WGS. EndoV-seq has been involved in the evaluation 
of both on- and off-target deamination by ABE, and offers some 
clues to improve the specificity of ABE. EndoV-seq has been 
involved in utilizing EndoV (deoxyinosine 3′ endonuclease) in 
vitro for nicking the DNA strand containing the  inosine which 
is deaminated by ABE. The processed samples are then sub-
jected to WGS for identification of off-target sites.[73] However, 
the specificity of BE and off-target assessment needs an endo-
nuclease for recognition of base I, the deaminated product of 
base A. EndoV from Thermotoga  maritimais is a repair enzyme 
that has the ability to recognize the deoxyinosines and hydro-
lyze the second phosphodiester bond 3′ of the inosine base that 
results in nicked DNA.[74]
5.10. VIVO (Verification of in Vivo Off-Targets)
VIVO is a very sensitive in vivo method which robustly detects off-
target effects caused by CRISPR/Cas nucleases in a genome-wide 
scale.[75] VIVO has been tested in vivo where a gRNA was delib-
erately designed with random sequence to check whether Cas9 
can induce bona fide off-targets in mouse livers. VIVO demon-
strated that correctly designed gRNAs can direct the efficient 
in vivo editing in mouse livers without any detectable off-target 
mutations. VIVO is therefore suitable to define and quantify the 
off-target mutations of Cas9 proteins in whole organisms.[75]
6. Algorithms/Tools for sgRNA Target Finding and 
Evaluation, and Prediction of Off-Target Effects
A variety of experimental systems are widely being used to 
investigate the off-target effects of sgRNAs and they show dif-
ferent outcomes regarding the extent of off-targets.[76] Many 
algorithms have been applied for the prediction of off-target 
effects and many Cas9 proteins with high specificity have 
successfully been produced for minimizing Cas9 promis-
cuity.[37,40,44,77–82] However, sequencing-based approaches have 
been widely used to experimentally validate a variety of Cas9 
off-targets that are not fully explained by such algorithms,[29,67] 
raising an interesting question about mechanisms of binding 
of Cas9 complexes and cleavage of off-targets.[40] Many tools 
have been developed and widely used on the basis of mismatch 
information, including the number and location of the mis-
matches, finding and evaluating the potential off-target sites. 
Several groups have used these algorithms for defining poten-
tial off-target sites (Table 2).
6.1. PEM-seq (Primer-Extension-Mediated Sequencing)
PEM-seq has been developed and widely used to detect off-target 
effects and determination of specificity and editing efficiency of 
CRISPR/Cas9.[46] LAM-HTGTS has been combined with targeted 
sequencing by PEM-seq for the effective analysis of CRISPR/
Cas9 induced off-target mutations via translocation capture. 
PEM-seq can characterize off-target sites and other abnormal 
chromosomal structures, such as genome-wide translocations, 
small indels, and large deletions induced by Cas9. Furthermore, 
PEM-seq has been employed for testing a variety of extensively 
used methods which were developed for reducing Cas9 off-target 
activity, whereby PEM-seq can assess comprehensively the speci-
ficity and editing efficiency of CRISPR/Cas9. This could greatly 
help in choosing an appropriate GE strategy for given loci.[46]
Adv. Sci. 2020, 7, 1902312
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6.2. CRISPR-PLANT v2
CRISPR-PLANT is a platform for helping researchers in 
designing and constructing specific gRNAs for CRISPR/
Cas9-mediated GE in plants. CRISPR-PLANT v2 detects every 
 off-target, where other tools have failed in detecting a subset 
of hidden sequences. However, off-target sequences with gaps 
were not detected by other tools.[83] This is important because of 
the considerable off-target activity by CRISPR/Cas9 at sites with 
one gap or one to three mismatches.[20,29,30] Most of the tools 
use Bowtie, though Bowtie has been designed for mapping up 
to 1024 bases of sequence when only one hit is expected to exist 
in the target genome.[84]
6.3. CCTop (CRISPR/Cas9 Target Online Predictor)
CCTop has widely been used to provide an intuitive user inter-
face with easily adjustable default parameters by the user. It has 
the ability to identify and rank all the candidate sgRNA target 
sequences in accordance with their off-target score, and shows 
the entire output. CCTop has been widely applied in gene inac-
tivation, HDR and NHEJ experiments. CCTop helps to rapidly 
and efficiently identify the high quality target sites.[79] It has 
numerous options for providing the list of top candidates to 
both a beginner and the expert, with complete documentation 
and flexible options. Therefore, the user will be well informed 
to select the suitable target sites.[79]
6.4. CROP-IT (CRISPR/Cas9 Off-Target Prediction and 
 Identification Tool)
CROP-IT is a web-based tool that has been widely used to 
perform improved site predictions of binding and cleavage of 
off-target editing. CROP-IT has the ability to integrate biolog-
ical information in the genome wide scale from current Cas9 
editing profile data base (binding and cleavage). CROP-IT has 
been shown to outperform current computational algorithms 
for predicting the Cas9 binding and cleavage sites. CROP-IT 
outputs scores and ranks the potential off-targets, enabling the 
improvements in the prediction of Cas9 editing profile and 
then accurate gRNA design.[85]
6.5. CHOPCHOP
CHOPCHOP is a web-based tool that has been developed to 
accept numerous inputs (pasted sequences, genomic regions, 
gene identifiers) and provides a range of options to select any 
Adv. Sci. 2020, 7, 1902312
Table 2. Algorithms for detection of off-target effects.
Algorithm Description Web source Refs.
PEM-seq Detection of off-target effects. Simultaneously determines the editing 
efficiency and specificity of CRISPR/Cas9
– [46]
CRISPR-PLANT v2 CRISPRPLANT v2 detects every off-target http://www.genome.arizona.edu/crispr2/ [83]
CCTop Employs position-dependent weight coefficients in their off-target scoring 
algorithms
http://crispr.cos.uni-heidelberg.de [79]
CROP-IT Scoring potential off-target sites by the division of protospacer into three 
segments with weight coefficients optimized/rained with ChIP-Seq data
http://www.adlilab.org/CROP-IT/homepage.html [85]
CHOPCHOP Rapid and easy selection of the optimal CRISPR/Cas9 or TALEN target 
sequences in genes from various organisms
https://chopchop.cbu.uib.no/,  
https://chopchop.rc.fasharvard.edu
[86]
CHOPCHOP v2 Web-based tool for GE based on TALEN and CRISPR. A powerful and 
intuitive tool that serves both beginners and experienced users
http://chopchop.cbu.uib.no [138]
CFD score A scoring tool for a mismatch position and sequence-dependent  
off-target
http://www.broadinstitute.org/rnai/public/analysis-tools/
sgrna-design 
http://research.microsoft.com/en-us/projects/azimuth/
[78]
Feng Zhang lab’s Target 
Finder
Employs position-dependent weight coefficients in their  
off-target scoring algorithms
http://crispr.mit.edu/ [18,38]
CT-Finder Predicts genomic off-target sites http://bioinfolab.miamioh.edu/ct-finder [87]
CRISPOR A web-based tool which finds gRNAs in an input sequence and ranks 
them according to different scores evaluating potential off-targets in the 
genome and predicts on-target activity
http://crispor.org [44]
CRISPR-GE Expedites experimental design and analyzes mutations for genome 
editing based on Cpf1/CRISPR/Cas9 in various organisms including 
plants
http://skl.scau.edu.cn/ [89]
An ensemble learning 
method
Predicts the off-target sites of sgRNAs https://github.com/penn-hui/OfftargetPredict [48]
Cas-OFFinder Searches the potential off-target sites in user-defined sequences or given 
genome
http://www.rgenome.net/cas-offinder/ [77]
MD Analysis of the molecular function of CRISPR/Cas9 – [139]
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target. CHOPCHOP uses algorithms with efficient sequence 
alignment for minimizing search times, and prediction of off-
target editing of TALENs and CRISPR/Cas9. Additionally, for 
each potential target site, the primer candidates and restric-
tion sites are visualized to facilitate an efficient pipeline for 
generation and validation of mutations. CHOPCHOP has 
been considered as a valuable tool for genome engineering, 
allowing users for rapidly and easily select the optimum target 
sequences for CRISPR/Cas9 or TALEN in genes from a wide 
range of organisms.[86]
6.6. CFD (Cutting Frequency Determination) Score
CFD score is a tool which has been widely used for scoring 
mismatch position and sequence-dependent off-targets with 
240 fitting parameters.[78] CFD score has been used to detect 
statistically significant increases in predicted off-target sites 
for lethal sgRNAs. In addition, it has been suggested that the 
sgRNAs with higher off-target risk are more easily improperly 
removed in the negative selection module. However, the avoid-
ance of such uninhibited sgRNAs leads to improved library 
performance. CFD score predicts the probability of off-target 
cutting and allows the decrease of majority of off-target editing 
with high efficiency.[78]
6.7. CT-Finder (CRISPR Target Finder)
CT-Finder is web tool developed by Zhu et al. with multiple 
functions.[87] Besides the routine service for the off-target pre-
diction for the CRISPR/Cas9 system, it also can be applied for 
the precise target prediction in two novel systems: RNA-guided 
FokI nuclease (RFNs) and Cas9 D10A nickases (Cas9 n). 
Like other web tools, CT-Finder can supports quite a few 
input setting including maximum numbers of gaps and num-
bers of mismatch as well as seed region length, with a very 
friendly and convenient visualization interface-JBrowse, which 
can visualize off-target and on-target sequences in a genomic 
context, providing users the incorporation of user inputs for 
various important features, such as PAM sequence and gRNA 
length.
6.8. CRISPOR
CRISPOR, as a web tool, was developed by Concordet and 
Haeussler and designed for the gRNAs selection in a wide 
range genomes type. More than 150 genomes have been added 
into the data of this tool in the past 3 years. Once the candidate 
sgRNA sequences loading, CRISPOR will rank them with dif-
ferent scores regarding possible off-target editing in the desired 
genome, and also to predict on-target activity. It offers an inclu-
sive solution from cloning, expression, and selection of gRNA 
and provides primers required for analysis of guide activity 
and possible off-targets.[88] CRISPOR ignores the candidate 
off-target mutation with the off-target score < 0.1 for the NGG 
PAM and those with a score less than 1.0 for NGA and NAG 
PAMs. CRISPOR currently supports 113 genomes.[44]
6.9. CRISPR-GE
CRISPR-GE is an integrated web-based tool for expediting all 
experimental settings and analyses modifications by CRISPR/
Cas/Cpf1 systems in various living organisms, including 
plants. It offers a robust toolkit for designing the target sgRNAs 
(targetDesign), primer design to construct the sgRNA expres-
sion cassettes, prediction of off-target sites (offTarget) as well 
as the amplification of the target sites with genomic fragments 
(primerDesign). CRISPR-GE provides a practical and compre-
hensive solution for GE in plants.[89]
6.10. An Ensemble Learning Method
Through this method, off-target sites of a sgRNA from its thou-
sands of candidates can be detected genome-wide. This method 
is based on the occurrence of considerable differences in GC 
count and the preferences in a mismatch between the positive 
on-target-off-target sequence pairs and those negative ones. 
This method enhances the efficiency of off-target site prediction 
as compared to other computational methods, and can identify 
more off-target sites consist with bona fide detections through 
high-throughput methods. According to two case studies, it is 
efficient in the selection of optimal sgRNAs for treatment of 
certain genetic disorders.[48]
6.11. Cas-OFFinder
Cas-OFFinder is a versatile tool that detects possible off-target 
mutation sites in a user-defined sequence or a given genome. 
Compared with other tools for prediction of the off-target sites 
of RGEN, Cas-OFFinder has no limitations to the number 
of mismatches, allowing modifications in Cas9-recognized 
PAM sequences, the vital protein component in RGENs. In 
any sequenced genome, Cas-OFFinder allows rapid detection 
of potential off-target editing without restraining the PAM 
sequence or the number of mismatched bases.[76]
7. Tools to Design Target-sgRNA for GE
It is imperative to design sgRNA properly in order to eliminate 
lethal off-targeting by GE tools. Various kinds of tools have 
been developed widely for designing sgRNAs with maximum 
accuracy (Table 3).
7.1. CRISPR-P 2.0
CRISPR-P 2.0 is an online web tool providing services for 
designing sgRNA sequences and minimizing the possibili-
ties of off-target editing. It could design sgRNA for more than 
50 plant genomes, including nearly all available major crop 
 species (such as Rice, cotton, maize, wheat and so on) with high 
quality assembled genomes to date. It uses an adapted scoring 
method to rate the on-target efficiency and off-target potential 
of sgRNAs for SpCas9. The scoring method in CRISPR-P 2.0 
Adv. Sci. 2020, 7, 1902312
www.advancedsciencenews.com
1902312 (10 of 16) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
relies on recent research on the efficiency and specificity of 
SpCas9 in GE. CRISPR-P 2.0 supports the designing of guide 
sequence for Cpf1 and other many CRISPR/Cas systems.[90] It 
provides a comprehensive analysis of guide sequences, such as 
the GC content, secondary structure of sgRNA, sites for restric-
tion endonucleases.[91]
7.2. E-CRISP
E-CRISP is an online application for designing gRNAs. It pro-
vides the identification of target sequences which are comple-
mentary to the gRNA ending in a 3′ PAM N(G or A)G that is 
essential for the recruitment of Cas9 nuclease to cleave dsDNA. 
It utilizes a fast indexing system to search a binary interval tree 
and binding sites for the rapid annotation of putative gRNA 
target sites. E-CRISP also supports the reevaluation of CRISPR 
constructs for on- or off-target sites as well as targeted genomic 
loci.[92]
7.3. Breaking-Cas
Oliveros et al (2016) developed Breaking-Cas System which 
is a tool to design gRNAs for CRISPR/Cas9 and other newly 
emerging variants. This tool offers unique features, possibly 
supports all eukaryotic genomes available in ENSEMBL and 
ENSEMBLGENOMES database. It is very flexible to iden-
tify and score the PAM motif sites (5′ or 3′) and its position. 
It also offers a valuable service for the assessing off-targets of 
the gRNAs with the length of 18–25 nucleotides. Notably, the 
input form (providing a FASTA file) is very efficient and flexible 
(supporting the process of many sequences in a single run with 
multiple entries) , which is freely accessible on-line like other 
tools.[93]
7.4. CasFinder
The CasFinder system was developed by Aach et al.,[94] which 
revises the tool originally developed for identifying potential 
off-targets generated by CRISPR/Cas9 system based on the 
combined querying for PAMs and seeds.[6] This tool has several 
distinguishing features: this system offers flexible choosing in 
gRNA length, PAM sequence, number of mismatch and gaps; 
the JBrowse was introduced for the first time to visualize the 
off-target and on-target sites, which is very convenient and 
efficient for the user to evaluate the off-targets effects within 
the genomic context. Notably, the CasFinder also supports the 
off-target prediction for two newly emerging CRISPR/Cas vari-
ants RFNs and Ca9n, which are relied on the paired gRNAs 
and exhibited higher target specificity compared to the single 
CRISPR variant.
8. Strategies to Increase Target Editing Efficiency 
and Avoid or Minimize Off-Target Editing of 
CRISPR/Cas System
Potential off-target effects remain a major concern for many 
medical applications. Several efforts are being made to decrease 
off-target activity of the CRISPR/Cas9 and for this purpose, high 
fidelity Cas9 variants and many other promising approaches are 
being developed for reducing possible off-target activity, such as 
the optimization of sgRNA design,[95] transcriptome analysis,[96] 
and functional screening after dCas9 treatment.[97] Additionally, 
off-target effects can be reduced either by increasing the speci-
ficity of target site DNA/RNA cleavage mediated by nuclease e or 
by decreasing the duration of the nuclease expression for mini-
mizing the chances of accumulation of off-target mutations.[98] 
Various other strategies and efforts include direct delivery 
(RNP complex),[99,100] separate Cas9 binding approaches (paired 
Cas9 nickases),[101] truncated sgRNAs (small guide RNAs),[102] 
and tunable systems (small-molecule induction of Cas9, light-
activated and intein-inactivated Cas9).[103–105] Tunable or induc-
ible systems regulate the Cas 9 working time, which is helpful 
decrease the undesirable DNA cleavage to the genome, which 
is one of major causes for the off-target mutation. For example, 
the cleavage activity of Cas 9 could be blocked by two bacterio-
phage proteins AcrIIA2, AcrIIA4 (anti-CRISPR proteins) after 
Cas9 cutting the target specific region.[106] In recent years, serial 
Cas9 variants with high fidelity have been developed through 
optimizing and delineating the structure of Cas9 including 
eSpCas9(1.1), SpCas9-HF1, Sniper-Cas9, HypaCas9, xCas9(3.7), 
evoCas9, and SpCas9-NG.[37,80,107–110]
Off-targets introduce ambiguity into scientific discoveries 
about the functions of any genes, and confounds potential 
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Table 3. Tools to design target-sgRNA.
Tools Description Web source Ref.
CRISPR-P 2.0 Web service for computer-aided designing of sgRNA with minimal chances of  
off-target potentials
http://cbi.hzau.edu.cn/CRISPR2/ [91]
E-CRISP Web-based application for designing gRNA sequences. Provides experiment-oriented 
design and flexible output parameters that enables the design of many libraries
http://www.e-crisp.org/,  
http://www.e-crisp.org/E-CRISP/
[92]
Breaking-Cas system Web service for designing gRNAs for CRISPR/Cas9 system and other  
newly generated CRISPR/Cas systems available via ENSEMBL
http://bioinfogp.cnb.csic.es/tools/breakingcas [93]
CasFinder Extends and modifies a method to search the potential off-targets  
for Cas9 by using queries that combine PAMs and seeds
http://arep.med.harvard.edu/CasFinder [18]
CRISPR Design Tool A computational tool, facilitating the selection and validation of sgRNAs  
and prediction of off-target
http://www.genome-engineering.org/ [38]
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 therapeutic applications of CRISPR/Cas9 and other GE tools. 
The strategies to detect off-target GE effects have been catego-
rized into different groups, including mathematical and com-
putational predication, validation of experimental off-target 
cleavage, modification of Cas9-sgRNA delivery, engineering 
of gRNA, and the engineering of high-fidelity SpCas9.[111] 
 Different strategies to overcome or decrease off-target effects 
are illustrated as follows and in Figure 3.
8.1. Decreased Stem Cell or Plant Tissue Culture Time  
(to Avoid Somaclonal Variation)
Significant efforts are being made to understand the on- and 
off-target editing for assisting the design of CRISPR systems 
with desirable efficiency. The prolonged timing for the stem 
cell or plant tissue culture means the longer duration of the 
nuclease expression, which will increase the risk of accumula-
tion of off-target mutations. Meanwhile, the somaclonal varia-
tions generated in the tissue culture and regeneration process 
will be dramatically accumulated and they will be the other kind 
of “off-target” or unwanted mutations and have a more signifi-
cant negative impact on the edited cell lines, plants than the 
off-target editing mediated by nuclease. Therefore, it is very 
important to introduce any system which can reduce the time, 
cost, and labor in generating any transgenic mutant. Several 
systems, including tissue-culture free systems,  DNA-free sys-
tems, transient systems, and VIGS-mediated sgRNA delivery 
systems are likely to be suitable in generating mutants in 
shorter time, with low cost and reduced reliance on expert 
knowledge.
8.2. High-Quality Reference Genome
Substantial progress has been made to avoid, and aid in the 
detection of genome-wide off-targets in an unbiased manner, 
and in the prediction of off-target effects.[112] These methods 
are often limited by their reliance on a reference genome for 
evaluation of efficacy, efficiency, and accuracy of gRNA. Cur-
rent efforts have primarily focused on the improvement of the 
 reference genome, and so great care must be taken in the selec-
tion of a suitable reference genome for designing sgRNAs. A 
recent report from our group regarding the off-target effects 
of CRISPR-Cas9 in cotton revealed that there has consider-
able genetic variation (up to 1 million SNPs and 14000 Indels) 
between the reference genome (cotton cultivar “TM-1”) used 
for the sgRNAs design and the genome of the genotype used 
for genetic transformation (cotton cultivar “Jin 668” with 
higher plant regeneration ability). Our suggestion is that if you 
choose certain genotype to do genome editing, you should use 
the high-quality genome of this genotype to design sgRNAs. 
Adv. Sci. 2020, 7, 1902312
Figure 3. Several promising approaches have been adopted to decrease the off-target activity of CRISPR/Cas systems, including decreased stem 
cell or plant tissue culture time, high-quality reference genome, optimal sgRNA designing, and high-fidelity CRISPR/Cas variants. These systems are 
 engineered for greater precision, target specificity with no or at least much lower off-target activity than wild-type Cas9.
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Unfortunately, except the rice, Arabidopsis these model species, 
most genotypes in major crop species (cotton, maize, wheat, 
rapeseed, soybean, sorghum) used for genetic transformation 
do not have high-quality genome sequences and the available 
reference genomes in these species are form different geno-
types (Normally, these genotypes can’t be used for plant tissue 
culture and genetic transformation because of low regeneration 
ability).[63]
8.3. Optimal sgRNA Design
Once high-quality reference genomes for desired strains/cul-
tivars/cells/lines are available, the following vital step is the 
selection of an appropriate tool to design sgRNAs and predict 
off-targets. A variety of tools have been developed for designing 
sgRNAs which are being used to design optimum sgRNA 
sequences for minimum chances of off-targeting, as discussed 
above.
8.4. Improved CRISPR/Cas Systems
8.4.1. CBEs and ABEs (Cytosine and Adenine Base Editors, BEs) 
System for Base Editing
As introduced earlier, BEs are chimeric proteins made up of a 
catalytic domain and a DNA targeting modules with the capa-
bility to deaminate an adenine or a cytidine. These proteins do 
not require the generation of DSBs for editing of DNA bases, 
and therefore to decrease the occurrence of random indels at 
on-target sites and mitigate the off-target effects.[15,27] These are 
promising novel tools to obtain precise gene alterations nec-
essary for trait improvement and disease treatment.[26] CBEs 
and ABEs have been developed by fusing a nickase-type Cas9 
(nCas9) protein harboring a deaminase domain, which con-
verts the C-T (C>T) and A-G, respectively, at the target site of 
a sgRNA.[23,113] However, ABEs allow the efficient and precise 
A-T to G-C base pairs conversion of targeted region within 
the editing window, generating minimal by-products. ABEs 
have been shown to induce minimum DNA off-target editing, 
whereas RNA off-target editing with ABEs has not been studied 
in detail. ABE retains low DNA off-targeting activity with 
decreased indel formation. Through decoupling the RNA and 
DNA editing activity, these ABE variants enhance the accuracy 
of adenine base editing via minimizing the off-target editing 
activities of both RNA and DNA.[114]
In a study by Grünewald et al.,[115] CBEs or ABEs were 
shown to be involved in inducing the guide-RNA-independent 
editing in a transcriptome-wide scale of RNA bases. The selec-
tive inhibition of off-target RNA editing (SECURE)-BE3 sys-
tems was created to ensure reduction of unwanted RNA-editing 
activity. The CBEs and ABEs have been found to exhibit the 
activity of RNA off-target editing and have the ability to self-edit 
their own transcripts, thus lead to the heterogeneity in the RNA 
sequences of BEs.[116]
Another study by Grünewald et al.[116] showed the ability 
of CBE with rat APOBEC1 for causing the wide-ranging 
cytosines deamination in human cells transcripts at the 
 transcriptome-wide scale which induces thousands of Cytidine-
to-Uracil edits. CBE-induced RNA edits have been found in 
noncoding and coding regions of proteins, and generating dif-
ferent types of mutations, such as nonsense, missense, splice 
site, and untranslated region mutations at 5′ and 3′. They also 
show that an ABE7 has the ability to induce transcriptome wide 
RNA edits.
Zhou et al.[117] quantitatively evaluated single nucleotide vari-
ations (SNVs) that have been induced by CBEs or ABEs. The 
result show that these two systems can generate considerable 
off-target SNVs in RNA sequences. Consequently, by engi-
neering the deaminases, three CBE and one ABE variants have 
been found to reduce off-target mutations in RNA SNVs while 
maintaining of an efficient on-target activity with DNA.
8.4.2. xCas9 and Cas9-NG
xCas9 and Cas9-NG are engineered versions of SpCas9, which 
show great potential to improve target specificity and extend 
target range. These Cas9 variants have been evaluated in the 
crop and model plant species, rice. xCas9-3.7 is an efficient 
xCas9 variant showing targeted editing ability at up to 16 can-
didate NGN PAMs combinations such as NGG, NG, GAA, 
and GAT. xCas9 has been shown to have the broadest range of 
PAM recognition ability, such as GAT, GAA, and NG. xCas9 has 
various applications in human cells. Compared with SpCas9, 
xCas9 shows higher DNA specificity with considerably lower 
off-target activity at all NGG PAMs on a genome-wide scale, 
and the minimal off-target activity at genomic regions with 
non-NGG target sites.[118] xCas9 has the ability to target canon-
ical NGG PAMs while Cas9-NG is a preferred enzyme to rec-
ognize relaxed PAMs for plant GE.[119] The crystal structure of 
 Cas9-NG reveals that the newly added non-base-specific interac-
tions can compensate the deficiency of base-specific recognition 
with the third nucleotide base, which enable the recognition of 
NG PAM. It also introduces indels in human cells at endog-
enous targeting regions with NG PAMs.[110]
8.4.3. Cas9n (Cas9 Nickase) and dCas9 (Dead Cas9)
Paired Cas9 nickase (Cas9n) is a mutated version of Cas9 where 
HNH or RuvC domains is inactivated by introducing a H840A 
or D10A alteration. Paired nickases are guided by two sgRNAs 
targeted to neighboring sites for inducing the offset nicks that 
generate the indel mutation.[98,101,120,121] Cas9 nickases have 
also been used as the targeting module that results in high fre-
quencies of base editing.[101,122]
The working model of dead Cas9 (dCas9) is very similar with 
Cas9n and has been to produce epigenetic and genetic modi-
fications by fusing with different functional domains, such as 
single base mutations, to any specific DNA target sites. Since 
the base editing does not generate DSBs, both the Cas9 nickase 
and dCas9 have been utilized to edit specific loci by targeting 
the deaminase domains. Cytidine and adenine deaminases 
change their respective nucleotides (C and A) into T and G 
bases, which provide many opportunities for editing of any 
gene. Such base editing enzymes offer an excellent potential 
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for their applications in basic biology, treatment of genetic dis-
orders, and crop trait improvement.[123]
8.4.4. Tru-gRNAs (Shorter/Truncated Guide RNAs for  
On-Target Site)
gRNAs with shortened length over the first 20 bp to 17/18 bp 
show reduced off-target site modification without changing on-
target efficiency.[101] For example, the use of truncated sgRNAs 
with a shortened 5′-end of 17 or 18 nt significantly decreases 
undesirable mutagenic effects at off-target sites in mamma-
lian cell systems.[102] Similarly, in plants, the use of truncated 
sgRNA in a CRISPR/Cas9 system using a constitutive promoter 
resulted in high on-target mutation rates with no off-target 
effects detected.[124] Moreover, combining truncated sgRNAs 
with pairs of Cas9 nickase led to further reductions in off-target 
mutations.[101]
8.4.5. SpCas9-HF1 (High-Fidelity Engineered Variants of SpCas9)
SpCas9-HF1 is a variant having high fidelity and is designed 
to decrease nonspecific DNA interactions. SpCas9-HF1 has 
on-target activity similar to WT SpCas9 and has been tested 
with > 85% of sgRNAs in human cells. This system preferen-
tially interacts with typical nonrepetitive sequences has been 
observed to render most off-target events, which is nonde-
tectable by break capture and targeted sequencing strategy 
in a genome-wide scale. Due to its extraordinary accuracy, 
 SpCas9-HF1 offers an alternate to WT SpCas9 for therapeutics 
and clinical applications.[80]
8.4.6. eSpCas9 (Enhanced Specificity of SpCas9)
The eSpCas9 decreases off-target activities and maintains effi-
cient on-target editing. The eSpCas9 can act as a highly useful 
for GE tool that require a high specificity such as clinical 
medicine. The enhanced specificity of GE could be obtained 
by reducing the binding with nontarget strand via a rationally 
 generated eSpCas9 (K848A, K1003A, R1060A).[107]
8.4.7. ADAR2-Based RNA Base Editors
RNA BEs have been developed for modulating a range of 
biological processes by editing RNAs. For example, ADAR2 
deaminates adenosine to inosine, which is read as guanine by 
the translational machinery.[125] A recently repurposed RNA-
guided ribonuclease system uses CRISPR/Cas13 that enables 
the editing of mRNA sequences and adenosine to inosine 
editing by using a catalytically inactive Cas13 protein and the 
deaminase activity of ADAR2. This system, and similar other 
systems, have excellent potential to treat genetic diseases.[126] 
However, the significant advantage of the application of RNA 
editing systems is that they do not introduce a permanent mod-
ification within the genome. Thus, these systems provide much 
better safety and ethical use compared to DNA base editing in 
humans.[125] However, all the Cas13 proteins have the two enzy-
matically distinctive ribonuclease activities required for optimal 
interference.[127]
8.4.8. CRISPR-Cpf1-RNP (Recombinant CRISPR-Cpf1 
Ribonucleoprotein)
The in vivo use of CRISPR-Cpf1 has been found to exhibit 
decreased off-target activity because that the Cpf1 will be 
degraded by endogenous proteases system in the target cells 
after Cpf1 performs its on-target editing.[128,129] Nuclease 
concentration within the cell,[68] delivery method (RNP vs 
plasmid)[68,98,130] as well as more complex cellular properties, 
such as chromatin accessibility[131,132] have been shown to affect 
editing outcomes significantly and are generally missed by in 
vitro off-target assays.
8.4.9. HypaCas9 (Hyper-Accurate Cas9 Variant)
HypaCas9 system enables a higher genome-wide fidelity 
without affecting the on-target genome editing in human cells. 
This system offers the potential as an improved approach to 
modify and rationalize the balance between nuclease activation 
and target recognition for precise GE.[37]
9. Concluding Remarks and Future Perspectives
A range of molecular tools are emerging for the GE of a wide 
range of living organisms, including animals, humans, and 
major plants species. These tools are proving themselves 
to be increasingly precise, efficient, effective, and reliable. 
CRISPR/Cas9 and other CRISPR/Cas systems are consid-
ered as revolutionary technologies that enable modifying 
nuclear genomes with unprecedented precision because of 
their accuracy, efficiency, cost-effectiveness, and ease of use. 
Other CRISPR/Cas systems are being developed for effi-
cient GE. However, GE can introduce a variety of off-target 
mutations that can result in deleterious phenotypes, and so 
off-target effects potentially limit the widespread use of GE. 
To overcome this problem, various systems are being devel-
oped to reduce off-target effects, such as the newly gener-
ated CRISPR/Cas systems and the improvement of existing 
systems. Moreover, a range of techniques have been applied 
to detect off-target mutations, and to improve the on-target 
efficiency and decrease/avoid off-target effects. In most cases, 
off-target mutations can be ameliorated by specific sgRNAs 
selection with less predicted off-targets, based on a robust 
reference genome sequence. After selection of the refer-
ence genome, it is critical to choose an appropriate tool for 
designing of sgRNAs and then the efficient delivery system 
(with the minimum level of somaclonal variations) of GE 
components into the target cells. Different software have 
been developed that can be used to design specific sgRNAs 
with negligible chances of off-targeting, but more research is 
needed to further increase the on-target specificity and avoid 
or mitigate the off-target effect.
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